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Abstract In 2006 the protein TDP-43 was identiﬁed as
the major ubiquitinated component deposited in the
inclusion bodies found in two human neurodegenerative
diseases, amyotrophic lateral sclerosis and frontotemporal
lobar degeneration. The pathogenesis of both disorders is
unclear, although they are related by having some overlap
of symptoms and now by the shared histopathology of
TDP-43 deposition. Now, in 2008, several papers have
been published in quick succession describing mutations in
the TDP-43 gene, showing they can be a primary cause of
amyotrophic lateral sclerosis. There are many precedents in
neurodegenerative disease in which rare single-gene
mutations have given great insight into understanding
disease processes, which is why the TDP-43 mutations are
potentially very important.
Introduction
Rapidly rising life expectancy is forcing many of the
world’s societies to see neurodegenerative diseases as a
wider social and economic issue. Such diseases have
always been devastating for sufferers and their carers, but
aging societies are facing a broader burden resulting from
the lack of effective treatments. There is hope for disorders
such as Alzheimer disease (AD), where now we have a
good understanding of pathogenesis and novel treatments
are on the horizon. However, two neurodegenerative dis-
orders that remain in urgent need of attention, and that
mainly but not exclusively affect the aging population, are
amyotrophic lateral sclerosis (ALS) and frontotemporal
lobar degeneration (FTLD).
ALS is the third most common neurodegenerative cause
of adult death after AD and Parkinson disease (http://
www.statistics.gov.uk/StatBase) and the lifetime risk of
dying from ALS lies between 1/400 and 1/1000 (Boillee
et al. 2006; Pasinelli and Brown 2006), and in the UK 1 in
400 death certiﬁcates is issued for ‘‘motor neuron disease’’
(J. Stevens, personal communication). In ALS the upper
motor neurons that run from the brain into the spinal cord
and the lower motor neurons that extend from the spinal
cord out to the muscles degenerate, leading inexorably to
paralysis and death, typically within 3–5 years of diagnosis
(Boillee et al. 2006; Pasinelli and Brown 2006; Schymick
et al. 2007; Valdmanis and Rouleau 2008). Intellect usu-
ally remains intact and no effective treatments are
available. Up to approximately 10% of ALS is familial
(FALS), usually autosomal dominant, and mutations in the
ubiquitously expressed enzyme superoxide dismutase 1
(SOD1) are causative in less than 20% of FALS (Deng
et al. 1993; Rosen et al. 1993) and in approximately 1% of
sporadic ALS (SALS) (Pasinelli and Brown 2006). Other
rare ALS mutant genes are known, usually associated with
variants of ALS rather than the classic typical midlife onset
disease (Boillee et al. 2006; Pasinelli and Brown 2006;
Schymick et al. 2007; Valdmanis and Rouleau 2008).
FTLD is the most common cause of presenile (below 65
years of age) dementia after AD (Forman et al. 2007;
Harvey et al. 2003; Ratnavalli et al. 2002). Affected
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Mamm Genome (2008) 19:299–305
DOI 10.1007/s00335-008-9117-xindividuals have a range of characteristic traits that reﬂect
degeneration in the frontal and temporal lobes of the
brain—the areas that control behavior, emotions, and lan-
guage. Early symptoms typically manifest as language
difﬁculties and inappropriate behavior (Neary et al. 1998).
Up to 40% of FTLD is thought to be familial with geneti-
cally heterogeneous causes. Causative mutations have been
identiﬁed in several genes, including those encoding tau
(Hutton et al. 1998; Poorkaj et al. 1998; Spillantini et al.
1998), charged multivesicular body protein 2B (CHMP2B)
(Skibinski et al. 2005), and progranulin (GRN) (Baker et al.
2006; Cruts et al. 2006), and others remain to be found.
Mutations have also been identiﬁed in the valosin-con-
taining protein (VCP) gene in inclusion body myopathy
associated with Paget disease of bone and frontotemporal
dementia, in which frontotemporal dementia can be, but is
not always, a feature (Watts et al. 2004).
At ﬁrst glance ALS and FTLD appear to be different
disorders; however, clinicians have noted for some time
that there are overlaps. FTLD symptoms are reported in up
to 20% of ALS cases (Valdmanis and Rouleau 2008; Van
Deerlin et al. 2008) and there are other intriguing con-
nections such as families that segregate both disorders
(Morita et al. 2006; Valdmanis et al. 2007) and imaging
studies which show frontal deﬁcits in ALS patients (Kato
et al. 1993). A recent study has shown that progranulin is a
modiﬁer of ALS disease progression (Sleegers et al. 2008),
although this was not replicated in another study (Picker-
ing-Brown et al. 2008).
Importantly, in common with several other neurodegen-
erative disorders, ALS and FTLD both present with
aggregates of misfolded proteins in the cytoplasm and/or
nucleus of neurons. Ubiquitinated inclusion bodies have
been reported in the cytoplasmof neurons of bothSALS and
FALScasesandinmutant SOD1transgenicmice thatmodel
FALS (for further discussion see Boillee et al. 2006; Pasi-
nelli and Brown 2006). FTLD is subdivided into two classes
based on the content of the inclusion bodies: (1) those with
tau-positive and ubiquitin-negative inclusions (tauopathies)
and (2) more common forms with ubiquitinated but tau-
negative inclusions known as FTLD-U, including PGRN,
VCP, and CHMP2B mutations (reviewed in Mackenzie and
Rademakers 2007). ALS and FTLD-U cases both present
with cytoplasmic ubiquitin-positive, tau-negative inclusions
indicating that there are at least some common pathway(s)
involved in the pathogenesis of these diseases.
TDP-43—the new kid on the block
Research into ALS and FTLD-U was radically redirected by
the appearance of a new player in 2006. In that year,
Neumann, Trojanowski, Lee, and colleagues provided a
molecular connection between these disorders by ﬁnding
that a protein called the TAR DNA-binding protein (TDP-
43) is the major protein in the inclusion bodies in both
disorders (Neumann et al. 2006), which was quickly con-
ﬁrmed (Arai et al. 2006). Some authors now refer to the
TDP-43 inclusion positive types of ALS and FTLD-U as
different forms of the same neurodegenerative disorder:
TDP-43 proteinopathy (Cairns et al. 2007; Kwong et al.
2008; Winton et al. 2008). TDP-43 positive inclusions have
now also been reported in cases of Alzheimer disease, Pick
disease, dementia with Lewy bodies, and other neurode-
generative disorders, and are seen in glia as well as neurons
(Amador-Ortiz et al. 2007; Freeman et al. 2008; Geser
et al. 2008; Hasegawa et al. 2007; Higashi et al. 2007;
Nakashima-Yasuda et al. 2007; Neumann et al. 2007).
TDP-43 is a 414-residue, 43-kDa protein, ﬁrst identiﬁed
as a binding partner of the TAR DNA element of the human
immunodeﬁciency virus (Ou et al. 1995). Currently we
know that TDP-43 is a ubiquitously expressed, highly con-
served nuclear protein encoded by a 6-exon gene (TARDBP
on human chromosome 1p36.2). The protein consists of two
RNA recognition motifs and a glycine-rich domain (Fig. 1).
It is found in nuclear bodies, colocalized with SMN and
gemin proteins, and may function as a transcriptional
repressor and as an activator of exon skipping, or in other
roles such as in miRNA biogenesis, apoptosis, and cell
division (Ayala et al. 2005, 2008; Buratti et al. 2001; John-
son et al. 2008; Winton et al. 2008). In the TDP-43
proteinopathies TDP-43 is depleted from the nucleus and is
sequestered as hyperphosphorylated insoluble aggregates in
the nucleus, perikarya, and dystrophic neurites (Neumann
et al. 2006). Perturbation of the trafﬁcking of TDP-43
between the nucleus and cytoplasm is thought to lead to the
formationoftheseaggregates;brainsamplesfrombothALS
and FTLD-U are enriched for a smaller (*25 kDa) phos-
phorylated C-terminal fragment and high-molecular-weight
ubiquitinated species (Neumann et al. 2006; Winton et al.
2008). Inhibition of autophagy can also lead to the relocal-
ization of TDP-43 from the nucleus to the cytoplasm in vitro
(Filimonenko et al. 2007).
Intriguingly, while TDP-43 is deposited in sporadic and
familial FTLD-U and in sporadic and non-SOD1 familial
ALS (Kwong et al. 2008; Neumann et al. 2006), it is not
found in inclusions in SOD1 FALS (Mackenzie et al. 2007;




G85R transgenic mouse models of FALS (Robertson
et al. 2007).
TDP-43 is a criminal, not just a bystander
The identiﬁcation of TDP-43 in ALS and FTLD-U inclu-
sion bodies immediately led to surveys of patient cohorts to
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123ﬁnd either association with or mutations in the gene. All
returned with negative results (e.g., see Gijselinck et al.
2007; Rollinson et al. 2007; Schumacher et al. 2007),
leading to the reasonable conclusion that TDP-43 deposi-
tion may simply be a consequence of disease and therefore
possibly of less interest in providing novel insight into the
cause of these diseases. However, in 2008 all this has
changed with the publication of ﬁve articles, all of which
report rare TDP-43 mutations in sporadic and familial ALS
in patients of different ethnicities (mainly but not exclu-
sively Caucasian) (Gitcho et al. 2008; Kabashi et al. 2008;
Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki
et al. 2008). In summary (Fig. 1, Table 1), all the muta-
tions lie in exon 6 except for one in exon 4. The FALS
cases are autosomal dominant with some variability in
presentation, bulbar and limb onset cases, some with more
or less lower motor neuron loss and different ages of onset
and rates of progression, but all fairly classic FALS. No
dementia is found, although Kabashi et al. (2008) report
apathy, major anxiety, and agitation in two individuals. For
cases in which postmortems have been carried out, TDP-43
deposition has been found in the brains of affected indi-
viduals (Van Deerlin et al. 2008; Yokoseki et al. 2008).
The mutations are already starting to give some insight
into pathogenesis (Gitcho et al. 2008; Kabashi et al. 2008;
Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki
et al. 2008). Disruption of protein interactions is one pos-
sible disease mechanism. Most mutations lie in the
C-terminal, a glycine-rich region that may mediate inter-
actions with proteins, including heterogeneous
ribonucleoproteins. Also, some of the mutations found in
this region could increase phosphorylation by substituting
threonine or serine residues or through the creation of a
new protein kinase A site (Sreedharan et al. 2008). This
may result in disruption of protein interactions and/or
disruption of transport through the nuclear pore complex.
In transfected cell lines and patient lymphocytes some
variants also show a clearly increased propensity to
aggregate and to produce a lower-molecular–weight,
detergent-insoluble protein product (Kabashi et al. 2008;
Sreedharan et al. 2008; Yokoseki et al. 2008). One muta-
tion, D169G, lies in the ﬁrst RNA-binding motif and may
affect RNA binding (Kabashi et al. 2008). When mutant
TDP-43 is electroporated into the neural tube of developing
chick embryos, two different mutations showed a reduction
in rate of maturation of the neural tube with an increase in
apoptotic nuclei, suggesting a toxic gain of function or
dominant negative effect (Sreedharan et al. 2008).
It is noteworthy that just one mutation lies in exon 4,
within the ﬁrst RNA recognition motif (RRM 1), whereas
the other 13 mutations identiﬁed so far occur in exon 6, in
the putative protein interaction domain. This raises the
question of whether the exon 4 mutation (D169G) is a
genuine pathogenic mutation and, if so, if it leads to disease
via a different effect on TDP-43 function than the other
mutations. D169 is a highly conserved amino acid (Kabashi
et al. 2008) and the mutation was absent in 360 ethnically
matched controls from France (Kabashi et al. 2008), as
well as in 872 nonethnically matched controls (700 British,
172 Australian) for which all exons of TDP-43 were
sequenced in the study of Sreedharan et al. (2008). The
absence of the mutation in a large number of controls and
Fig. 1 TDP-43 mutations in ALS. TDP-43 is encoded by a 6-exon
gene, of which exons 2-6 are protein coding (top). The TDP-43
protein contains four known functional domains: a nuclear localiza-
tion sequence, two central RNA Recognition Motifs (RRM1 and
RRM2), and a C-terminal glycine-rich domain, predicted to mediate
protein-protein interactions. All disease mutations so far are found in
the glycine-rich domain (encoded by exon 6), with the exception of
one mutation in RRM1 (encoded by exon 4). A mutation in the
nuclear localization domain has been reported in two unaffected
controls (data compiled from Gitcho et al. 2008; Kabashi et al. 2008;
Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki et al.
2008)
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Numbers of individuals 
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Other mutations  Reference 
D169G
  s 56 Spinal
G287S
  s 65 Bulbar
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  s 30 Spinal
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N390S
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et al., 2008 
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M337V
  f 47
3 Spinal,









































et al., 2008 
SALS = sporadic amyotrophic lateral sclerosis; FALS = familial amyotrophic lateral sclerosis; MND = motor neuron disease; GRN = pro-
granulin; SOD1 = Cu/Zn superoxide dismutase 1; MAPT = microtubule-associated protein tau; CHMP2B = chromatin modifying protein 2B;
VAPB = synaptobrevin-associated membrane protein B; ANG = angiogenin; DCTN1 = dynactin.
Each mutation is absent in the control group. Fourteen missense mutations lie in the glycine-rich domain of the protein encoded by exon 6 of
TARDBP and one mutation lies in the ﬁrst RNA binding domain (D169G)
1 mean age of onset,
2FTLD and related disorders, see text for details,
3all exons sequenced,
4only the speciﬁc variants were analyzed, full
sequencing was not performed,
5only exon 6 sequenced,
6method of detection not described,
fmutation found in familial ALS, or
sindividuals
with no known family history of ALS
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pathogenic role; however, absence in a larger number of
ethnically matched controls and functional data or the
identiﬁcation of further mutations in RRM 1 will be
required to fully resolve this issue. If D169G is pathogenic,
then it suggests that mutations in the C-terminal domain,
and the RRM1 domain, which has been shown to be
essential for the RNA-binding ability of TDP-43 (Buratti
and Baralle. 2001), affect the function of TDP-43 in a
similar way, such as a general loss of function, or that there
are different ways to disrupt TDP-43 function and still lead
to disease.
Rare single-gene defects, protein aggregates, and
neurodegeneration—sounds familiar
The identiﬁcation of the major protein in neurodegenera-
tive disease inclusion bodies, followed by ﬁnding rare
mutations in the gene encoding this protein, is a powerful
route to understanding pathogenesis and is turning into a
surprisingly common approach in neurodegenerative dis-
eases. It is exempliﬁed by the classic example of ﬁnding
mutations in the amyloid precursor protein (APP) gene that
encodes the Abeta peptide deposited in the plaques of
Alzheimer disease; it revolutionized our understanding of
AD (Hardy and Selkoe 2002). Similar rare dominant sin-
gle-gene mutations have also been found in the proteins
that aggregate in Parkinson disease, prion diseases, and
tauopathies, for example, also giving us great insight into
the pathogenesis of these disorders. The articles that
reported on TDP-43 mutations in ALS have shifted the
focus of attention on this protein from being deposited as a
by-product of disease processes to actually being a causa-
tive agent that triggers the processes resulting in neuronal
death. From this point investigations will proceed using
transgenic and knockout mice and a variety of different
cellular systems to understand the link between mutation
and disease.
Many questions need to be addressed, such as does
TDP-43 take on a toxic gain of function when mutated in
ALS, as happens with SOD1 mutations in ALS? Will TDP-
43 mutations be found in cases of FTLD-U, and if not, why
not? How important is timing? Does having a germline
TDP-43 mutation give rise to ALS which might develop
into FTLD-U if individuals lived long enough? Another
question is: What separates TDP-43 ALS from SOD1
ALS? These two diseases are very similar at a clinical
level, but clearly different pathways are affected for at least
some of the pathogenesis. We assume that there are many
parallel cellular pathways, which, if disrupted can lead to
the same outcome. TDP-43 ALS and SOD1 ALS may
allow the investigation of this phenomenon.
The new mutations found in TDP-43 are a breakthrough
for ALS and FTLD-U research and we are looking forward
to seeing what new discoveries they herald to help us treat
and ultimately cure these terrible neurodegenerative
diseases.
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